Short Bowel Syndrome (SBS) Patient Pool Market Expected to Reach USD 2.7 Billion by 2034

Short Bowel Syndrome (SBS) is a rare, chronic malabsorption disorder caused by the surgical removal or congenital absence of portions of the small intestine, leading to impaired nutrient absorption. Patients often suffer from diarrhea, malnutrition, weight loss, dehydration, and vitamin deficiencies, requiring lifelong nutritional support and, in severe cases, parenteral nutrition (PN).

Download Full PDF Sample Copy of Market Report @ https://exactitudeconsultancy.com/request-sample/71165

SBS is categorized as a rare disease, but its impact on quality of life and healthcare systems is profound. The growing prevalence of gastrointestinal surgeries, Crohn's disease, and other underlying conditions that lead to bowel resection are fueling the SBS patient pool worldwide. Pharmaceutical innovations, nutritional advancements, and government support for rare disease management are expected to drive consistent growth in the next decade.

Market Overview
• Market Size (2024): USD 1.4 billion
• Forecast (2034): USD 2.7 billion
• CAGR (2025-2034): 6.7%

The SBS market is expanding due to rising surgical interventions, greater awareness, and expanding use of growth factors like teduglutide. Nutritional support therapies and parenteral nutrition remain crucial, while drug innovation is reshaping treatment.

Key Highlights:
• Rising incidence of gastrointestinal surgeries and Crohn's disease increasing patient pool.
• Parenteral nutrition remains the cornerstone of treatment but has long-term risks.
• Novel drugs like teduglutide (GLP-2 analog) are revolutionizing SBS management.
• Expanding rare disease programs and orphan drug policies supporting R&D.

Segmentation Analysis
By Product Type:
• Pharmaceuticals
o GLP-2 Analogues (Teduglutide, Glepaglutide - pipeline)
o Growth Factors & Biologics
o Other Supportive Medications
• Nutritional Support
o Parenteral Nutrition (PN)
o Enteral Nutrition
o Oral Supplements
• Surgical Interventions
o Intestinal Transplantation
o Bowel Lengthening Procedures

By Platform:
• Small Molecules
• Biologics
• Nutritional Formulations

By Technology:
• Parenteral Nutrition Systems
• Enteral Feeding Devices
• Clinical Research Platforms

By End Use:
• Hospitals
• Specialty Clinics
• Home Care Settings
• Research Institutes

By Application:
• Adult SBS Patients
• Pediatric SBS Patients
• Clinical Trials

Segmentation Summary:
Pharmaceutical therapies, led by GLP-2 analogs, represent the fastest-growing category, while parenteral nutrition continues to dominate due to its critical role in patient survival. Hospitals remain the largest end-use segment, though home-based parenteral nutrition programs are expanding globally.

Explore Full Report here: https://exactitudeconsultancy.com/reports/71165/short-bowel-syndrome-sbs-patient-pool-market

Regional Analysis
North America
• Largest market with ~43% share in 2024.
• U.S. leads due to advanced parenteral nutrition programs and strong adoption of teduglutide.
• Supportive rare disease frameworks and reimbursement policies drive demand.
Europe
• Accounts for ~30% share.
• Germany, UK, and France lead in patient management and clinical trial activity.
• Strong orphan drug designation programs supporting pharmaceutical innovation.
Asia-Pacific
• Fastest-growing region with CAGR of ~7.8%.
• Rising incidence of Crohn's disease and GI surgeries in China, Japan, and India.
• Expanding healthcare infrastructure and government support for rare disease care.
Middle East & Africa
• Smaller share due to limited infrastructure and high costs of parenteral nutrition.
• Gradual improvements in tertiary hospitals and specialty clinics driving growth.
Latin America
• Brazil and Mexico drive demand with growing patient awareness and improving nutritional support access.
Regional Summary:
North America and Europe dominate due to advanced healthcare infrastructure, rare disease policies, and access to GLP-2 analogs, while Asia-Pacific shows the fastest growth due to rising prevalence and healthcare investments.

Market Dynamics
Key Growth Drivers:
• Growing SBS patient pool due to GI surgeries and Crohn's disease prevalence.
• Increasing adoption of GLP-2 analogues and biologics.
• Expansion of home parenteral nutrition programs.
• Strong support from orphan drug designation and rare disease funding.

Key Challenges:
• High treatment costs, especially for long-term PN and GLP-2 analogues.
• Complications of PN, including infections and liver damage.
• Small patient pool limiting large-scale R&D.
• Limited awareness and access in emerging economies.

Latest Trends:
• Pipeline development of next-generation GLP-2 analogues (glepaglutide).
• Integration of AI in nutritional monitoring and patient management.
• Expansion of telehealth for rare disease patients on PN.
• Partnerships between pharma companies and hospitals for SBS research.

Get Your Exclusive Offer with up to 10% Discount : https://exactitudeconsultancy.com/checkout/?currency=USD&type=single_user_license&report_id=71165

Competitor Analysis
Major Players in the Market:
• Takeda Pharmaceutical Company Limited (Teduglutide - Gattex/Revestive)
• Zealand Pharma (Glepaglutide - pipeline)
• Shire plc (now part of Takeda)
• Baxter International Inc. (parenteral nutrition solutions)
• Fresenius Kabi AG
• Nestlé Health Science
• Pfizer Inc.
• Novartis AG
• Johnson & Johnson Services, Inc.
• Dr. Falk Pharma GmbH

Competitive Summary:
Takeda dominates the SBS pharmaceutical space with teduglutide, the first GLP-2 analog approved for SBS. Zealand Pharma is advancing next-generation GLP-2 therapies. Baxter, Fresenius, and Nestlé lead the nutritional support segment with PN and enteral feeding solutions. The competitive landscape is shaped by innovation in biologics and expanding access to PN programs.

Conclusion
The Short Bowel Syndrome (SBS) Patient Pool Market, valued at USD 1.4 billion in 2024, is projected to reach USD 2.7 billion by 2034, growing at a CAGR of 6.7%. Rising surgical interventions, growing Crohn's disease prevalence, and orphan drug-driven pharmaceutical innovation are shaping the market outlook.

Key Takeaways:
• GLP-2 analogs like teduglutide are revolutionizing SBS therapy.
• Parenteral nutrition remains the backbone of patient survival but has long-term risks.
• North America and Europe dominate, while Asia-Pacific shows fastest growth.
• Pipeline drugs and home care PN expansion are critical future opportunities.

The next decade will see SBS management transition from dependence on parenteral nutrition to more advanced biologics and patient-centered home care models, creating significant opportunities for pharma innovators and healthcare providers.

This report is also available in the following languages : Japanese (短腸症候群(SBS)患者プール市場), Korean (단장증후군(SBS) 환자 풀 시장), Chinese (短肠综合征(SBS)患者池市场), French (Marché des patients atteints du syndrome de l'intestin court (SIC)), German (Markt für Patientenpools mit Kurzdarmsyndrom (SBS)), and Italian (Mercato dei pazienti affetti da sindrome dell'intestino corto (SBS)), etc.

Request for a sample of this research report at (Use Corporate Mail ID for Quick Response) @ https://exactitudeconsultancy.com/reports/71165/short-bowel-syndrome-sbs-patient-pool-market#request-a-sample

Our More Reports:

Moderate to Severe Plaque Psoriasis ( ONLY CANADA DATA) Market
https://exactitudeconsultancy.com/reports/71425/moderate-to-severe-plaque-psoriasis-only-canada-data-market

Nail Diseases Market
https://exactitudeconsultancy.com/reports/71427/nail-diseases-market

Palmoplantar Keratoderma (PPK) Market
https://exactitudeconsultancy.com/reports/71429/palmoplantar-keratoderma-ppk-market

About Us
Exactitude Consultancy is a market research & consulting services firm which helps its client to address their most pressing strategic and business challenges. Our market research helps clients to address critical business challenges and also helps make optimized business decisions with our fact-based research insights, market intelligence, and accurate data.
https://bulletin.exactitudeconsultancy.com/

https://www.thehealthanalytics.com/

https://www.analytica.global/

https://www.marketintelligencedata.com/

https://www.marketinsightsreports.com/

https://exactitudeconsultancy.com/

Connect Us:
Irfan Tamboli
PHONE NUMBER +1 (704) 266-3234
EMAIL ADDRESS: sales@exactitudeconsultancy.com

This release was published on openPR.